Cometriq‚Ñ¢ by Exelixis, Inc.

Exelixis is a biopharmaceutical company committed to developing and commercializing small molecule therapies for the treatment of cancer. The company is focusing its proprietary resources and development efforts on COMETRIQ® (cabozantinib), its first commercial product. COMETRIQ was nominated for its activity in progressive, metastatic medullary thyroid cancer, a disease state for which, until recently, there had been few treatment options for patients. The product, which was approved in November 2012 and made commercially available in January 2013, inhibits the activity of tyrosine kinases including RET, MET, and VEGFR2. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment.